News
12-11-2010, 05:04 AM
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)...
More... (http://mnt.to/f/3NXH)
More... (http://mnt.to/f/3NXH)